Next Biomedical Co.,Ltd. (KOSDAQ:389650)

Next Biomedical Revenue

Next Biomedical had revenue of 4.94B KRW in the quarter ending June 30, 2026, with 24.28% growth. This brings the company's total for the last twelve months to 17.79B, up 46.25% year-over-year. In the year 2025, Next Biomedical had annual revenue of 16.48B with 72.67% growth. That makes Next Biomedical the 35,920th largest company in the world by revenue and 2,301st in South Korea.

• Revenue (ttm): 17.79B
• Revenue Growth: +46.25%
• P/S Ratio: 12.66
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 225.14B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Endoscopic Hemostatic Agent 8.26B 86.5%
• Vascular Embolic Microspheres 788.73M 8.3%
• Vascular Embolic Microspheres -F 489.21M 5.1%
• Other 8.40M 0.1%

By Geography

• Europe 4.40B 46.1%
• United States 4.39B 46.0%
• South Korea 676.12M 7.1%
• Other 68.96M 0.7%

Fiscal year ended Dec 31, 2024 See the full Next Biomedical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	16.48B	6.93B	72.67%
Dec 31, 2024	9.54B	4.66B	95.46%
Dec 31, 2023	4.88B	2.09B	74.67%
Dec 31, 2022	2.80B	527.74M	23.28%
Dec 31, 2021	2.27B	6.63M	0.29%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error